CTPH-02 / Celltrion - LARVOL DELTA

Discovery of the synergistic dual-payload antibody-drug conjugate (CTPH-02) by combination of MMAE and novel payloads (AACR 2025) - "By conjugating a dual-payload with two-different mechanisms of action to HER2 antibody(trastuzumab), the resulting ADC(CTPH-02) was confirmed to show synergistic effect in terms of cytotoxicity. Very excitingly, CTPH-02 shows significantly high synergistic efficacy in the case of cell lines with low HER2 antigen expression. These findings based on the right combination of two-different payloads open a new paradigm for ADC drug design strategies in cancer therapy in order to provide treatment options to wider range of cancer patients such as low TPS % with low IHC score."

Oncology

Celltrion Pharmaceuticals unveils self-developed 'ADC Dual Payload' platform for the first time at AACR [Google translation] (BioTimes) - "Celltrion Pharmaceuticals combined MMAE (monomethyl auristatin E, microtubule inhibitor) and a new payload with trastuzumab, a HER2 antibody. As a result, it showed strong cytotoxicity through high synergy not only in cell lines with high HER2 expression but also in cell lines with low expression rates. In particular, even when using MMAE with a low DAR (drug-antibody ratio, drug-antibody ratio), it showed efficacy equivalent to or higher than that of a single payload ADC using MMAE with a high DAR. Celltrion plans to continue development with the goals of increasing the maximum tolerated dose (MTD) of CTPH-02, decreasing the minimum effective dose (MED), expanding the patient population by securing cytotoxicity in cell lines with low antigen expression, and reducing drug resistance."

Preclinical • Oncology